Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators : The Outcome of a Clinical Trial in Bangladesh
Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd..
BACKGROUND: Coronavirus disease (COVID)-19 has devasted the healthcare delivery system as well as social establishments of almost all countries of the world. However, vaccines for containing new cases of COVID-19 are yet to be realized. Also, presently available antiviral drugs and other standard of care (SOC) management strategies could not satisfactorily control COVID-19-related mortality, which has crossed the one million mark during the last 9 months. These facts present an emergent need for developing new, novel, and evolving therapeutic strategies for the management of COVID-19.
AIM AND OBJECTIVE: This cohort study represents a clinical trial in real-life situations in Bangladesh where two immune modulators were applied in patients with severe and critical COVID-19 patients.
MATERIALS AND METHODS: A total of 199 confirmed patients of COVID-19 were enrolled in this study. All of them had severe and critical COVID-19 and they were hospitalized at the intensive care unit (ICU) of the Combined Military Hospital (CMH), Dhaka, Bangladesh. All patients were positive for SARS-CoV-2 by polymerase chain reaction (PCR) of the nasal swab and they were endowed with severe pneumonia, multiple organ dysfunctions, and coagulopathy. The median percentage of lung involvement was 65%. The mean oxygen saturation was 83%. The patients received two immune modulators (tocilizumab and bevacizumab) in different combinations to retrieve broader insights about the safety and efficacy of immune modulators in COVID-19 management.
RESULTS: Out of the total 199 patients, 122 survived and 77 expired. A single dose of tocilizumab resulted in the survival of 71.5% (73 of 102 COVID-19 patients). On the other hand, a dramatic survival benefit was found in patients receiving bevacizumab (92%).
CONCLUSION: The study indicates that active treatment should be started as early as possible for COVID-19 patients as moderate COVID-patients may progress to more severe illnesses with grave consequences. The safety of two immune modulators has been recorded in this cohort of severe and critical COVID-19 patients. In order to have a proper use of these immune modulators, there is a need to accomplish controlled, blinded, and large-scale prospective studies with at least two arms.
HOW TO CITE THIS ARTICLE: Islam MA, Mazumder MA, Akhter N, et al. Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh. Euroasian J Hepato-Gastroenterol 2020;10(2):68-75.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Euroasian journal of hepato-gastroenterology - 10(2020), 2 vom: 19. Juli, Seite 68-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Islam, Md Azizul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bangladesh |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5005/jp-journals-10018-1327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320725855 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320725855 | ||
| 003 | DE-627 | ||
| 005 | 20240330235815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5005/jp-journals-10018-1327 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM320725855 | ||
| 035 | |a (NLM)33511068 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Islam, Md Azizul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators |b The Outcome of a Clinical Trial in Bangladesh |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. | ||
| 520 | |a BACKGROUND: Coronavirus disease (COVID)-19 has devasted the healthcare delivery system as well as social establishments of almost all countries of the world. However, vaccines for containing new cases of COVID-19 are yet to be realized. Also, presently available antiviral drugs and other standard of care (SOC) management strategies could not satisfactorily control COVID-19-related mortality, which has crossed the one million mark during the last 9 months. These facts present an emergent need for developing new, novel, and evolving therapeutic strategies for the management of COVID-19 | ||
| 520 | |a AIM AND OBJECTIVE: This cohort study represents a clinical trial in real-life situations in Bangladesh where two immune modulators were applied in patients with severe and critical COVID-19 patients | ||
| 520 | |a MATERIALS AND METHODS: A total of 199 confirmed patients of COVID-19 were enrolled in this study. All of them had severe and critical COVID-19 and they were hospitalized at the intensive care unit (ICU) of the Combined Military Hospital (CMH), Dhaka, Bangladesh. All patients were positive for SARS-CoV-2 by polymerase chain reaction (PCR) of the nasal swab and they were endowed with severe pneumonia, multiple organ dysfunctions, and coagulopathy. The median percentage of lung involvement was 65%. The mean oxygen saturation was 83%. The patients received two immune modulators (tocilizumab and bevacizumab) in different combinations to retrieve broader insights about the safety and efficacy of immune modulators in COVID-19 management | ||
| 520 | |a RESULTS: Out of the total 199 patients, 122 survived and 77 expired. A single dose of tocilizumab resulted in the survival of 71.5% (73 of 102 COVID-19 patients). On the other hand, a dramatic survival benefit was found in patients receiving bevacizumab (92%) | ||
| 520 | |a CONCLUSION: The study indicates that active treatment should be started as early as possible for COVID-19 patients as moderate COVID-patients may progress to more severe illnesses with grave consequences. The safety of two immune modulators has been recorded in this cohort of severe and critical COVID-19 patients. In order to have a proper use of these immune modulators, there is a need to accomplish controlled, blinded, and large-scale prospective studies with at least two arms | ||
| 520 | |a HOW TO CITE THIS ARTICLE: Islam MA, Mazumder MA, Akhter N, et al. Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh. Euroasian J Hepato-Gastroenterol 2020;10(2):68-75 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bangladesh | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immune modulators | |
| 650 | 4 | |a Severe and critical COVID | |
| 650 | 4 | |a Tocilizumab | |
| 700 | 1 | |a Mazumder, Masudul A |e verfasserin |4 aut | |
| 700 | 1 | |a Akhter, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Huq, Akm Faizul |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Mahtab, Mamun |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Md Sakirul I |e verfasserin |4 aut | |
| 700 | 1 | |a Akbar, Sheikh Mf |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Euroasian journal of hepato-gastroenterology |d 2014 |g 10(2020), 2 vom: 19. Juli, Seite 68-75 |w (DE-627)NLM278670431 |x 2231-5047 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:2 |g day:19 |g month:07 |g pages:68-75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5005/jp-journals-10018-1327 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 2 |b 19 |c 07 |h 68-75 | ||